Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 5/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20865570 | 0.94 | DPP7 (0.32) | LARS1PSMB5PSMB1KDM4EUSP2 | |
| SCHEMBL18214190 | 0.89 | TLR7 (0.42) | LARS1KDM4EALDH1A1GLAGAA | |
| SCHEMBL22006150 | 0.88 | PSMB5 (0.38) | PSMB5MTNR1APSMB1ALDH1A1GAA | |
| SCHEMBL8150493 | 0.81 | TLR8 (0.37) | HTTTLR8 | |
| SCHEMBL7092075 | 0.80 | PSMB5 (0.32) | PSMB5MTNR1APSMB1KDM4EALDH1A1 | |
| SCHEMBL6924182 | 0.79 | MAOB (0.34) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL6441603 | 0.79 | HSP90AA1 (0.36) | KDM4EALDH1A1LMNACASP1CASP7 | |
| SCHEMBL6642504 | 0.78 | HDAC4 (0.35) | KDM4EALDH1A1CASP1HTTCASP7 | |
| SCHEMBL18546822 | 0.77 | EPHX1 (0.38) | ALDH1A1MAPT | |
| SCHEMBL6640299 | 0.75 | SHMT2 (0.37) | PSMB5KDM4EALDH1A1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-12-07 | — | — | US | claimed |
| EP-3902532-A1 | IMMUNE MODULATORY COMBINATIONS AND METHODS FOR TREATING CANCERS | Birdie Biopharmaceuticals, Inc. (KY) | 2021-11-03 | — | — | EP | claimed |
| WO-2020139618-A1 | IMMUNE MODULATORY COMBINATIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-07-02 | — | — | WO | claimed |
| US-20190269790-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2019-09-05 | — | — | US | claimed |
| US-20190016808-A1 | ANTI-EGFR COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2019-01-17 | — | — | US | claimed |
| US-20180110874-A1 | Compounds and Compositions for Immunotherapy | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2018-04-26 | — | — | US | claimed |
| US-9827329-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-11-28 | — | — | US | claimed |
| US-20170056391-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-03-02 | — | — | US | claimed |
| US-20170028079-A1 | Compounds and Compositions for Treating HER2 Positive Tumors | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2017-02-02 | — | — | US | claimed |
| US-20160375148-A1 | Compounds and Compositions for Treating EGFR Expressing Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2016-12-29 | — | — | US | claimed |
| EP-4691562-A2 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2026-02-11 | — | — | EP | disclosed |
| EP-4001311-B1 | ANTI-PD-L1/PD-1 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2025-11-05 | — | — | EP | disclosed |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-12-07 | — | — | US | disclosed |
| US-11786604-B2 | Compounds and compositions for treating HER2 positive tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-10-17 | — | — | US | disclosed |
| US-11786604-B2 | Compounds and compositions for treating HER2 positive tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-10-17 | — | — | US | disclosed |
| WO-2016004875-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2016-01-14 | — | — | WO | disclosed |
| WO-2015103990-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING EGFR EXPRESSING TUMORS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015103987-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HER2 POSITIVE TUMORS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015103989-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2015-07-16 | — | — | WO | disclosed |
| US-20030212093-A1 | Viricides, antitumor agents | 3M INNOVATIVE PROPERTIES COMPANY | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190269790-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | LARS1 3752/4885PSMB5 1601/4885MTNR1A 3481/4885 |
| US-20180110874-A1 | Compounds and Compositions for Immunotherapy | CD47, CD274, TP53 | LARS1 3752/4885PSMB5 1601/4885MTNR1A 3481/4885 |
| US-20170056391-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | TP53, MCL1, MSH2 | LARS1 3925/4885PSMB5 3712/4885MTNR1A 1395/4885 |
| US-20170028079-A1 | Compounds and Compositions for Treating HER2 Positive Tumors | ERBB2, EGFR, TP53 | LARS1 4679/4885PSMB5 1285/4885MTNR1A 1935/4885 |
| US-20160375148-A1 | Compounds and Compositions for Treating EGFR Expressing Tumors | EGFR, ERBB2, ERBB3 | LARS1 4498/4885PSMB5 1292/4885MTNR1A 3130/4885 |
| US-20190016808-A1 | ANTI-EGFR COMBINATIONS FOR TREATING TUMORS | EGFR, ERBB3, ERBB2 | LARS1 4093/4885PSMB5 2391/4885MTNR1A 901/4885 |
| US-11786604-B2 | Compounds and compositions for treating HER2 positive tumors | ERBB2, EGFR, TP53 | LARS1 4757/4885PSMB5 1268/4885MTNR1A 1817/4885 |
| US-20030212093-A1 | Viricides, antitumor agents | IFNG, IFNAR1, MAVS | LARS1 2996/4885PSMB5 3316/4885MTNR1A 2817/4885 |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | LARS1 3752/4885PSMB5 1601/4885MTNR1A 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.